Malewicz-Oeck Nathalie M, Aulenkamp Jana L, Oeck Sebastian, Scheffzük Claudia, Zahn Peter K, Hansen Wiebke, Schramm Alexander, Meyer-Frießem Christine H
From the Department of Anesthesiology, Intensive Care Medicine and Pain Management, Medical Faculty of Ruhr-University Bochum, BG University Hospital Bergmannsheil gGmbH, Bochum, Germany.
Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Anesth Analg. 2025 Mar 25. doi: 10.1213/ANE.0000000000007504.
After fracture-related surgery, chronic posttraumatic and/or postsurgical pain (CPSP) has a high incidence rate of up to 43% a year after surgery. Yet the underlying mechanisms are poorly understood. Murine and clinical evidence suggest immunological modulation of postsurgical pain. However, the specific cytokine profiles of patients who develop CPSP after fracture-related surgery remain to be determined. Therefore, we analyzed in an exploratory manner cytokines, chemokines and adipocytokines in patients with and without CPSP up to 1 year after fracture-related surgery.
A prospective longitudinal serum profiling of 30 patients with traumatic fractures that required osteosynthesis was conducted on the first day (D1), at 6 weeks (W6) and 1 year after surgery (Y1). Patients with CPSP at Y1 were compared to those who did not develop CPSP. A total of 22 pro- and anti-inflammatory serum cytokines, including adipocytokines, were quantified using Luminex technology. Statistical analyses included χ² test, t test, and Mann-Whitney U test, Spearman's rank correlations, and repeated-measures mixed models with Bonferroni correction for cytokine differences between patients with and without CPSP. Receiver-operating characteristic (ROC) curves evaluated the discriminatory ability of specific cytokines regarding the development of CPSP.
Patients with CPSP 1 year after surgery (n = 12/30, 40%) exhibited elevated resistin levels at Y1 (CPSP: 1.04 ± 1.04 vs no-CPSP: 0.41 ± 0.31 pg/mL; P < .001) as well as higher adiponectin levels at Y1 (CPSP: 9.37 ± 8.23 vs no-CPSP: 5.57 ± 2.75 μg/mL; P = .008). Patients with CPSP had higher Rantes/CCL5 (CC-chemokine ligand 5) levels immediately after surgery on D1 than patients without CPSP (mean difference [MD] = 5.5, confidence interval [CI], 1.7-9.3 ng/mL; P = .014). At W6 and Y1, adiponectin and CCL5 levels correlated with pain intensity in patients with CPSP (adiponectin: r = 0.50, P = .03; CCL5: r = -0.50, P = .03). Across the entire patient population, resistin levels were correlated with pain intensity (r = 0.34, P < .001; D1-Y1).
Our explorative cytokine analysis uncovered an imbalance in serum cytokines and chemokines during the chronification process in patients who developed CPSP 1 year after surgically treated fractures. In particular, adiponectin and resistin were noted to be novel biomarkers for CPSP development. These data provide preliminary insight into a potential unexplored crosstalk between chronic postoperative pain and adipocytokines in the chronification of CPSP, which remains to be further analyzed.
骨折相关手术后,慢性创伤后和/或术后疼痛(CPSP)的发生率很高,术后一年高达43%。然而,其潜在机制尚不清楚。小鼠和临床证据表明手术疼痛存在免疫调节。然而,骨折相关手术后发生CPSP的患者的特定细胞因子谱仍有待确定。因此,我们以探索性方式分析了骨折相关手术后1年内发生和未发生CPSP的患者的细胞因子、趋化因子和脂肪细胞因子。
对30例需要骨合成的创伤性骨折患者在术后第1天(D1)、6周(W6)和1年(Y1)进行前瞻性纵向血清分析。将Y1时发生CPSP的患者与未发生CPSP的患者进行比较。使用Luminex技术对包括脂肪细胞因子在内的总共22种促炎和抗炎血清细胞因子进行定量。统计分析包括χ²检验、t检验和Mann-Whitney U检验、Spearman等级相关性分析,以及采用Bonferroni校正的重复测量混合模型,用于分析发生和未发生CPSP的患者之间的细胞因子差异。受试者工作特征(ROC)曲线评估特定细胞因子对CPSP发生的鉴别能力。
术后1年发生CPSP的患者(n = 12/30,40%)在Y1时抵抗素水平升高(CPSP组:1.04 ± 1.04 vs无CPSP组:0.41 ± 0.31 pg/mL;P <.001),且在Y1时脂联素水平也较高(CPSP组:9.37 ± 8.23 vs无CPSP组:5.57 ± 2.75 μg/mL;P =.008)。术后第1天,发生CPSP的患者的趋化因子调节激活正常T细胞表达和分泌因子(Rantes/CCL5,CC趋化因子配体5)水平高于未发生CPSP的患者(平均差异[MD]=5.5,置信区间[CI],1.7 - 9.3 ng/mL;P =.014)。在W6和Y1时,脂联素和CCL5水平与CPSP患者的疼痛强度相关(脂联素:r = 0.5 0,P =.03;CCL5:r = -0.50,P =.03)。在整个患者群体中,抵抗素水平与疼痛强度相关(r = 0.34,P <.001;D1 - Y1)。
我们的探索性细胞因子分析发现,在手术治疗骨折后1年发生CPSP的患者的慢性化过程中,血清细胞因子和趋化因子存在失衡。特别是,脂联素和抵抗素被认为是CPSP发生的新生物标志物。这些数据初步揭示了慢性术后疼痛与脂肪细胞因子在CPSP慢性化过程中潜在的未被探索的相互作用,仍有待进一步分析。